ADTX - CIK 0001726711
Aditxt, Inc. trades as ADTX. In its fiscal 2025 annual report the company posted revenue of $3.19K, down 97.6% from the prior year and net income of -$43.10M. This page tracks Aditxt, Inc. through 548 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 4 fiscal years Aditxt, Inc.'s revenue declined from $105.03K to $3.19K, a compound annual decline rate of 58.2%. Net profit margin compressed from -44148.9% to -1349028.2% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| PRE 14A | - | 2026-05-22 |
| Quarterly report | 10-Q | 2026-05-20 |
| Major company event | 8-K | 2026-05-15 |
| NT 10-Q | - | 2026-05-15 |
| Major company event | 8-K | 2026-05-08 |
| Major company event | 8-K | 2026-05-01 |
| Insider trade | 4 | 2026-04-27 |
| Insider trade | 4 | 2026-04-23 |
The largest companies sharing Aditxt, Inc.'s SEC industry classification (pharmaceutical preparations).
Aditxt, Inc. reported revenue of $3.19K for fiscal year 2025, a decrease of 97.6% year over year.
In its latest fiscal year Aditxt, Inc. reported a net loss of $43.10M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.